.png){kind=logo}
Katherine Stueland is the CEO of GeneDx, who led the company from a financially challenged phase to profitability in just 3 years. Currently, she leads efforts to provide diagnostic services for rare-disease patients using genomic testing. With over 20 years of experience, she has scaled precision medicine companies, built strong teams, and earned recognition as a 2025 CNBC Changemaker for her patient-first leadership.
Katherine studied at Miami University in Ohio, where she graduated with a bachelor’s degree in science and English literature in 1997. She also thrived in Miami University’s Dance Theatre, developing creativity and discipline early on. These experiences shaped her communication skills and leadership style, laying the foundation for her future role as a strategic healthcare leader focused on patient advocacy and transformative innovation.
Katherine’s career has centered on driving meaningful change in healthcare through patient-centered leadership. She supported FDA approval for multiple rare disease therapies, such as the first HIV protease inhibitor and the first cancer immunotherapy. She became CEO of GeneDx in 2021, guiding the company’s growth in genomic diagnostics. Previously, she led Invitae’s commercial and communications strategies, supporting massive growth in test volume and revenue.
GeneDx applies artificial intelligence to genomic testing, accelerating rare disease diagnosis, improving accuracy, and delivering faster answers for families worldwide.
AI-driven Genome: The AI-driven Genome project uses machine learning to analyze extensive genomic data which helps GeneDx identify hidden genetic variations and solve difficult medical cases while providing rapid and accurate diagnosis for various rare diseases.
GeneDx Infinity Dataset: By leveraging one of the world’s largest clinically curated genomic datasets, GeneDx strengthens variant interpretation, refines phenotype matching, and improves confidence in difficult diagnoses for patients with rare conditions.
Neuro Genomics: It uses artificial intelligence to analyze childhood neurological disorders through genomic research which helps doctors achieve early diagnosis and reduce medical uncertainty while developing treatment plans for patients who have developmental or cognitive disabilities.
Variant Testing: The genetic analysis process of GeneDx enables families to conduct focused genetic testing which identifies specific mutations that help them assess hereditary patterns and calculate recurrence probabilities while making informed choices through their testing methods which deliver accurate results.
AI Cerebral Clarity: It uses advanced analytics to study cerebral palsy cases because it identifies previously unidentified genetic factors which lead to the condition while creating customized treatment plans that use molecular data for evidence-based care. .
AI Seizure: GeneDx uses artificial intelligence to enhance genomics research which explains the genetic causes of epilepsy. This technology helps physicians identify epilepsy types and select appropriate treatments while improving results for patients who experience unexplained seizures or who do not respond to standard therapies.
Under Katherine’s leadership, GeneDx developed its sequencing capabilities into a major operation and created the world’s biggest database of rare disease information. The company reached profitability while it increased diagnostic efficiency and developed better methods for making treatment decisions. Through her vision, GeneDx achieved Fast Company recognition while Katherine received a spot on CNBC's 2025 Changemakers list, which confirmed her impact on precision medicine.
At this time, Katherine Stueland remains free from any major public controversies. The company GeneDx has experienced market examination and investor dialogue about its business operations and insider trading practices but no legal proceedings or personal misconduct claims have been established against her.
